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Abstract
To improve implant biocompatibility, we developed a simple cost-effective thermal surface treatment allowing an increase in the
oxide layer thickness of a titanium (Ti) alloy used in orthopaedic implants. The goal of this study was to test in vitro the reaction of
osteoblasts to the developed surface treatment and to compare it to the osteoblast reaction to two other surface treatments currently
used in the practice of implant surgery. Quantiﬁcation of osteoblast gene expression on a large scale was used in this study. The
kinetics of gene expression over 120 h was followed for 58 genes to quantify the effect of the developed surface treatment. Twenty
eight genes were further selected to compare the effects of surface treatments on osteoblasts. Based on the genes studied, we could
propose a general pathway for the cell reaction according to the surface treatments used: (1) metal ion release changes the time
course of gene expression in the FAK pathway; (2) once the accumulation of metal ions released from the Ti surface exceeds a
threshold value, cell growth is diminished and apoptosis may be activated; (3) PTK up-regulation is also induced by metal ion
release; (4) the expression of Bcl-2 family and Bax may suggest that metal ions induce apoptosis. The developed treatment seems to
increase the Ti–6Al–4V biocompatibility as highlighted by the lower impact of this treatment by the different pathways studied, on
the lower inﬂammatory reaction that could be induced, as well as by the lower induced osteoblast apoptosis compared to the two
other surface treatments. r 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
When an implant is inserted into bone, it is expected
that an apposition of bone to the implant will occur, a
process called osteointegration [1]. From histological
examinations it has been found that implant loosening is
generally associated with the formation of ﬁbrous tissue
at the bone–implant interface [2].
It has been hypothesized that the differentiation
process of the peri-implant tissue could be driven either
by unfavourable mechanical situations [3] or by
inﬂammatory reactions following the phagocytosis of
wear particles [4] or by a combination of both [5]. We
recently showed that wear particles also inﬂuence
osteoblast behaviour [6–9]. Release of metal ions by
the implant and their effect on osteoblasts has been
mostly neglected until recently [10]. Due to the faster
process of ion released compared to wear particles
generation, interaction of osteoblast–ion would be
important to quantify as this phenomenon occurs soon
after prosthesis implantation.
To improve implant biocompatibility, we developed a
simple, cost-effective thermal surface treatment allowing
an increase in the oxide layer thickness of a titanium
alloy used for orthopaedic implants [11,12]. This oxide
layer acts as a barrier to keep ions from being released
into the body. Kinetic analysis showed a decrease in ion
release in the developed surface treatment [13].
Information on Ti–6Al–4V alloy treated surfaces
affecting osteoblasts is limited. The goal of this study
is then to test the osteoblast reaction to the developed
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surface treatment and to compare it to the osteoblast
reaction to two other surface treatments currently used
in the practice of orthopaedic implant surgery. The
strategy of this study is to perform a large-scale analysis
of gene expression in order to highlight possible
regulation pathways differentiated by the surface treat-
ments.
2. Materials and methods
2.1. Ti alloy surface preparations
Distal sections of forged Ti–6Al–4V alloy femoral
stems from the Ti-Mod Freeman hip implant were
supplied by Finsbury Instruments (Leatherhead, Surrey,
UK). The hip stems were cut into discs of 10mm
diameter and of 1mm thickness. The samples were
polished following a previously described procedure
[14]. The samples were then cleaned in 1% Triton
solution for 1 h and rinsed in deionized distilled water.
This treatment was used as control (C). The practice for
surface preparation of surgical implants involves a nitric
acid passivation treatment (P) with an immersion of the
implants in 30% nitric acid for 1 h [15]. We developed a
third treatment that we called aged treatment (A), which
consisted of the passivated treatment followed by ageing
in boiling deionized distilled water for 10 h [11,12]. The
samples were then sterilized and tested for endotoxin
contamination [14].
2.2. Cell culture
Primary human osteoblasts (hOB) were isolated from
pieces of cortical bone femur obtained during total hip
arthroplasty of a female patient (62 yr) following a
procedure previously described [16]. The osteoblastic
cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Sigma, Buchs, Switzerland) containing 10%
fetal bovine serum (Sigma), 1% PSF (100 , 10,000U/
ml Penicillin, 10,000mg/ml Streptomycin and 25mg/ml
Fungizone) (GibcoBRL, Life Technologies, Basel,
Switzerland) under a humidiﬁed 5% CO2/air atmo-
sphere at 371C. Osteoblasts passages lower than 4 were
used for the study. The osteoblasts were seeded at a
concentration of 380,000 cells/cm2 on each sample. In
order to have enough material to study gene expression,
6 samples of each treated surface were used (total cells
number: 1.62 107).
2.3. Gene expression study
Geneﬁlters GF211 (Research Genetics, Huntsville,
AL, USA) were used to monitor the expression of
12,626 genes. The collected RNA from the cells (5mg of
total RNA per condition) was processed according to
the manufacturer’s recommendations. The Pathwayst
software, developed by Research Genetics was used to
acquire the Geneﬁlters data. Normalization of gene
expression and data analysis was performed using Excel
(Microsoft Corporation, Redmond, WA, USA) and
2HAPI, a web-based bioinformatics software (http://
array.sdsc.edu). The kinetics of gene expression for hOB
incubated with the aged Ti–6Al–4V was measured at 4,
24, 48 and 120 h. The gene expression of cells incubated
4 h on the aged sample (A4) was chosen as the reference.
58 genes were selected and classiﬁed in 6 groups
according to adhesion, signal pathway and transcription
factors, growth factors and cytokines, differentiation,
mineralization and apoptosis. This selection represents a
panel of major genes expressed by osteoblasts [17,18].
Twenty-eight genes were speciﬁcally analysed to
compare the difference in gene expression between
different surface treatments. The results are presented
as the ratio of P/A and C/A for the corresponding gene
expression.
For both analyses, the difference in gene expression is
based on the experimental ﬁnding that upregulation by a
ratio higher than 2.5-fold or down-regulation by a ratio
lower than 0.4-fold (=1/2.5) has to be reached to be
considered as signiﬁcant. Sample control at 24 h was
analysed twice with two ﬁlters (C24(1) and C24(2)) and
showed good reproducibility (70% of the gene tested
had a gene expression variation lower than 10%
between the two analysis) (data not shown).
3. Results
The results presented in Table 1 are intended to
evaluate the kinetics of gene modulation of the surface
treatment A, while results presented in Table 2 are used
to compare gene expression with respect to the different
surface treatments (C, P, A). The functional description
of the chosen genes is given in Table 3. Sample A24 did
not have enough RNA for the analysis.
3.1. Kinetics of genes modulation by the surface
treatment A (Table 1)
From a quantitative point of view, in comparison
with A4, A48 has 213 up-regulated genes and 5 down-
regulated genes; A120 has 247 up-regulated genes and 5
down-regulated genes. More speciﬁcally, 58 genes were
selected and described in the following groups.
3.1.1. Adhesion
Collagen alpha-2 type I was up regulated 4.4-fold at
48 h and 3.48-fold at 120 h compared to A4. Integrin
a3; a5; a6;b1;b5; and ﬁbronectin were expressed by the
isolated hOB, but did not show a signiﬁcant difference
compared to A4.
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Table 1
Kinetic of gene expression for the aged Ti–6Al–4V surface (58 genes)
Acc Gene name A48/A4 A120/A4
Adhesion
U70312 Homo sapiens integrin binding protein Del-1 (Del1) mRNA 1.32 0.98
M59911 Human integrin alpha-3 chain mRNA 0.87 1.76
X06256 Human mRNA for integrin alpha 5 0.81 0.69
X53586 Human mRNA for integrin alpha 6 0.93 0.84
X07979 Human mRNA for integrin beta 1 0.55 0.79
M35011 Human integrin beta-5 mRNA 0.80 0.79
X53002 Human mRNA for integrin beta-5 0.68 0.61
X02761 Human mRNA for ﬁbronectin (FN precursor) 1.10 1.26
M10905 Human cellular ﬁbronectin mRNA 1.14 1.42
J03464 Human collagen alpha-2 type I mRNA 4.40 3.48
Signal pathway and transcription factors
L13616 Human focal adhesion kinase (FAK) mRNA 0.16 0.73
Z11695 Homo sapiens 40 kDa protein kinase related to rat ERK2 (MAPK1, MAPK2) 0.52 0.72
X80692 Cluster Incl X80692: Homo sapiens ERK3 mRNA (MAPK6) 0.49 0.41
AF002715 Cluster Incl AF002715:Homo sapiens MAP kinase kinase kinase (MTK1) 0.33 0.46
D87116 Human mRNA for MAP kinase kinase 3b 0.22 0.23
J04111 Human c-jun proto oncogene (JUN), clone hCJ-1 0.43 0.63
V01512 Human cellular oncogene c-fos 2.23 1.52
U02680 Human protein tyrosine kinase mRNA (PTK9) 0.50 0.63
M59371 Human protein tyrosine kinase (PTK) mRNA (EPHA2) 3.20 9.09
AF015254 Homo sapiens serine/threonine kinase (STK-1) mRNA 10.10 —
Growth factors and cytokines
M37825 Human ﬁbroblast growth factor-5 (FGF-5) mRNA 5.85 6.37
M60828 Human keratinocyte growth factor (KFG=FGF-7) mRNA (3853bp) 1.33 2.80
X03563 Human gene for Insulin-like growth factor I 4.38 —
M77349 Human transforming growth factor-beta-induced gene product (BIGH3) 1.31 0.82
X06374 Human mRNA for platelet-derived growth factor PDGF-A 1.41 1.83
M22488 Human bone morphogenetic protein 1 (BMP-1) mRNA 0.79 —
M22489 Human bone morphogenetic protein 2A (BMP-2A) mRNA — —
M22490 Human bone morphogenetic protein-2B (BMP-2B) mRNA 0.76 —
U43842 Homo sapiens bone morphogenetic protein-4 (hBMP-4) gene 0.43 0.57
M27968 Human basic ﬁbroblast growth factor (bFGF) mRNA 0.52 0.61
M28983 Homo sapiens interleukin 1 alpha (IL-1) mRNA — —
Differentiation
J04948 Human alkaline phosphatase (ALP-1) mRNA 1.22 1.34
L40992 Homo sapiens core-binding factor, runt domain, alpha subunit 1 (CBFA1) — —
L38517 Homo sapiens indian hedgehog protein (IHH) mRNA, 50 end — —
AF009801 Homo sapiens homeodomain protein (BAPX1) mRNA — —
Mineralization
J03040 Human SPARC/osteonectin mRNA 1.76 1.49
J04765 Human osteopontin mRNA 0.86 —
J04599 Human hPGI mRNA encoding bone small proteoglycan I (biglycan) 1.42 1.82
J05213 Homo sapiens sialoprotein precursor (IBSP) mRNA — —
Apoptosis
U37518 Human TNF-related apoptosis inducing ligand TRAIL mRNA — —
AF014794 Homo sapiens TNF related TRAIL receptor (TRAIL-R3) mRNA — —
M58603 Human NF-kB DNA binding subunit (NF-kappa-B) mRNA (NF-kB1) 0.85 0.92
L19067 Human NF-kB transcription factor p65 subunit mRNA (Rel A) 0.69 0.83
AF018253 Homo sapiens receptor activator of nuclear factor-kappa B (RANK) mRNA — —
AF022385 Homo sapiens apoptosis-related protein TFAR15 (TFAR15) 0.52 0.41
Y11588 Homo sapiens mRNA for apoptosis speciﬁc protein — —
AF053712 Homo sapiens osteoprotegerin ligand mRNA (TRANCE) — —
M37435 Human macrophage-speciﬁc colony-stimulating factor (M-CSF) 0.90 0.56
M13207 Human granulocyte-macrophage colony-stimulating factor gene (GM-CSF) — —
X03656 Human gene for granulocyte colony-stimulating factor (G-CSF=CSF-3) — —
M14745 Human bcl-2 mRNA (BCL2 (B-cell CLL/lymphoma 2)) — —
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3.1.2. Signal pathways and transcription factors
Focal adhesion kinase (FAK) and mitogen-activated
protein (MAP) kinases were down-regulated at 48 and
120 h. c-jun showed a 0.43-fold decrease and c-fos was
increased 2.23-fold for A48. Protein tyrosine kinase
(PTK9) showed a 0.5-fold decrease at 48 h. PTK
receptor was upregulated 3.20-fold at 48 h and increased
with time. Stem cell tyrosine kinase 1 (STK-1) was up-
regulated 10.10-fold at 48 h but undetected at 120 h.
3.1.3. Growth factors and cytokines
FGF-5 was up-regulated 5.85-fold and increased to
6.37-fold at 120 h. Keratinocyte growth factor
(KGF=FGF-7) was up-regulated 2.8-fold at 120 h.
Insulin-like growth factor (IGF-1) was up-regulated
4.38-fold at 48 h and not detected at 120 h. Transform-
ing growth-factor-b-induced gene (BIGH3) and platelet-
derived growth factor (PDGF-A) were detected, but did
not show signiﬁcant modulation. Most of the BMPs
were not detected (BMP-2A, BMP-3 and BMP-5, data
not shown) or down-regulated (BMP-1, BMP-2B and
BMP-4). Genes, which have been proved to be involved
in the process of osteoporosis, such as basic ﬁbroblast
growth factor, (FGF-2 or bFGF) and interleukin 1
alpha (IL-1a) were either absent or down-regulated
compared to the reference A4. The expression of pro-
inﬂammatory mediators including IL-6 and prostaglan-
din E-2 (PGE-2) were not detected (data not shown).
3.1.4. Differentiation
No signiﬁcant gene expression for core-binding factor
runt domain alpha subunit 1 (cbfa1), Indian hedgehog
(IHH) and homeodomain (BAPX1) was observed,
except for alkaline phosphatase (ALP), which had a
1.22-fold increase at 48 h and a 1.45-fold increase at
120 h.
3.1.5. Mineralization
SPARC/osteonectin, osteopontin (OPN), and bigly-
can (bone matrix glycoproteins), which are involved in
bone matrix mineralization, were detected. SPARC had
a 1.76-fold increase, OPN showed a 0.86-fold decrease
and biglycan showed a 1.42-fold increase at 48 h.
Sialoprotein precursor (IBSP) was absent.
3.1.6. Apoptosis
NF-kB1 showed a 0.85-fold decrease at 48 h and 0.92-
fold decrease at 120 h. NF-kB p65 showed a 0.69-fold
decrease at 48 h and a 0.83-fold decrease at 120 h. The
apoptosis related protein, TFAR15, showed a 0.52-fold
decrease at 48 h and a down-regulation of 0.41-fold at
120 h. Bcl-xL was up-regulated 6.42-fold at 48 h and up-
regulated 10.08-fold at 120 h. Bax isoform (alpha, beta,
gamma and delta) decreased over time.
3.2. Comparison of gene expression with respect to the
surface treatments C, P, A (Table 2)
In order to determine differential hOB gene expres-
sion from various treated surfaces, 28 genes were
selected from Table 1 and described in the following
groups.
3.2.1. Adhesion
Collagen alpha-2 type I expression increased by 1.45-
and 1.18-fold for samples P48 and C48 compared to A48,
and decreased by 0.70- and 0.74-fold for samples P120
and C120 compared to A120, respectively.
3.2.2. Signal pathways and transcription factors
FAK was up-regulated 4.25- and 6.63-fold for
samples P48 and C48 compared to A48. MAPK6 was
up-regulated 2.59-fold for sample C48 compared to A48.
c-jun increased by 1.84-fold for samples P48 and C48,
then decreased over time. c-fos expression was down-
regulated 0.27-fold for sample C48 and increased with
time for samples P and C. PTK9 was up-regulated 3.26-
fold for sample C48 compared to A48. Serine/threonine
kinases (STK-1) did not show difference between
samples.
Table 1 (continued)
Acc Gene name A48/A4 A120/A4
M13994 Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-
alpha protein (BCL2 (B-cell CLL/lymphoma 2) )
— 0
M13995 Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-
beta protein
— —
Z23115 Homo sapiens bcl-xL mRNA 6.42 10.08
L22473 Human Bax alpha mRNA 1.12 0.68
L22474 Human Bax beta mRNA 1.32 —
L22475 Human Bax gamma mRNA 0.47 —
U19599 Human Bax delta mRNA 0.99 0.67
The column A48/A4, represents the gene expression of osteoblasts seeded 48 h on aged sample divided by the gene expression of osteoblasts seeded 4 h
on aged sample. Similar nomenclature is used for the other columns. ‘‘—’’ means that no signal was measured. The value in bold type means
signiﬁcant expression (X2.5-fold: up-regulation; p0.4-fold: down-regulation). Acc is the Genebank accession number.
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3.2.3. Growth factors and cytokines
IGF-I expression decreased by 0.58-fold for sample
P48 and increased by 1.45-fold for sample C48. FGF-5
decreased at 48 h and increased at 120 h for samples P
and C compared to sample A. Keratinocyte growth
factor (KGF=FGF7) was up-regulated 4.90-fold and
7.07-fold for samples C48 and P48. FGF-2 (bFGF) was
up-regulated 3.19-fold for sample C48 and was increased
2.40-fold for P48.
3.2.4. Differentiation
ALP was not detected for samples P and C during the
test.
3.2.5. Mineralization
SPARC/osteonectin and biglycan had a 0.95-fold
decrease for samples P48 and C48 compared to sample
A48.
Table 2
Gene expressions between the aged treatment and control and passivated treatments (28 genes)
Acc Gene name P48/A48 C48/A48 P120/A120 C120/A120
Adhesion
J03464 Human collagen alpha-2 type I mRNA 1.45 1.18 0.70 0.74
Signal pathways and transcription factors
L13616 Human focal adhesion kinase (FAK) mRNA 4.25 6.63 1.04 1.22
Z11695 Homo sapiens 40 kDa protein kinase related to rat ERK2
(MAPK1 (mitogen-activated protein kinase 1), MAPK2)
2.32 2.17 0.85 0.76
X80692 Cluster Incl X80692:Homo sapiens ERK3 mRNA (MAPK6
(mitogen-activated protein kinase 6))
2.48 2.59 1.60 1.01
AF002715 Cluster Incl AF002715:Homo sapiens MAP kinase kinase kinase
(MTK1) mRNA
1.14 1.14 0.93 0.69
D87116 Human mRNA for MAP kinase kinase 3b 1.14 1.46 0.86 1.24
J04111 Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1 1.84 1.85 1.09 0.69
V01512 Human cellular oncogene c-fos 0.78 0.27 1.91 0.42
U02680 Human protein tyrosine kinase (PTK9) mRNA 2.16 3.26 1.54 0.81
AF015254 Homo sapiens serine/threonine kinase (STK-1) mRNA 1.30 0.89 0.84 1.48
Growth factors and Cytokines
X03565 Human IGF-I mRNA for insulin-like growth factor I 0.58 1.45 2.13 1.47
M37825 Human ﬁbroblast growth factor-5 (FGF-5) mRNA 0.55 0.78 1.80 1.06
S81661 Keratinocyte growth factor (KGF=FGF-7) 4.90 7.07 0.79 0.62
M60828 Human keratinocyte growth factor (KFG) mRNA 2.41 2.51 0.88 0.67
M27968 Human basic ﬁbroblast growth factor (bFGF) mRNA 2.40 3.19 1.02 1.13
Differentiation
J04948 Human alkaline phosphatase (ALP-1) mRNA — 0.86 — —
Mineralization
J03040 Human SPARC/osteonectin mRNA 0.95 0.94 0.90 1.34
J04599 Human hPGI encoding bone small proteoglycan I (biglycan) 0.93 0.94 0.84 1.25
Apoptosis
M58603 Human nuclear factor kappa-B DNA binding subunit (NF-kB1) 1.51 1.31 0.98 0.88
L19067 Human NF-kappa-B transcription factor p65 subunit (Rel A) 0.97 1.04 0.86 0.87
AF022385 Cluster Incl AF022385:Homo sapiens apoptosis-related protein
TFAR15 (TFAR15) mRNA
2.75 2.56 1.95 1.20
Z23115 Homo sapiens bcl-xL mRNA — — 0.90 0.14
L22473 Human Bax alpha mRNA 0.25 — 2.25 1.99
L22474 Human Bax beta mRNA 0.44 1.23 0.77 1.30
U19599 Human Bax delta mRNA 0.75 0.75 1.72 1.63
U09477 Human clone 53BP1 p53-binding protein mRNA, partial cds
(TP53BP1 (tumour protein p53-binding protein, 1))
— — — —
U58334 Human Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2)
mRNA (TP53BP2 (tumour protein p53-binding protein, 2))
1.31 1.14 0.80 1.01
M35878 Human insulin-like growth factor-binding protein-3 gene
(IGFBP3)
1.18 1.08 0.65 0.96
The column P48/A48, represents the gene expression of osteoblasts seeded 48 h on passivated sample divided by the gene expression of osteoblasts
seeded 48 h on aged sample. Similar nomenclature is used for the other columns.
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Table 3
The cellular functions of the chosen genes (based on GeneCards http://bioinfo.weizmann.ac.il/cards/ and [31]
Gene Genecard Cellular function
Adhesion
Integrin a3 ITGA3 Acts a receptor for ﬁbronectin, laminin and collagen
Integrin a5 ITGA5 Integrin alpha-5/beta-1 is a receptor for ﬁbronectin and ﬁbrinogen. It recognizes the sequence R-G-D in its
ligands
Integrin a6 ITGA6 Integrin alpha-6/beta-4 may mediate adhesive and/or migratory functions of epithelial cells. On platelets,
integrin alpha-6/beta-1 functions as a laminin receptor
Integrin b1 ITGB1 Associates with alpha-1 or alpha-6 to form a laminin receptor, with alpha-2 to form a collagen receptor, with
alpha-4 to interact with vcam-1, with alpha-5 to form a ﬁbronectin receptor and with alpha-8. Integrins
recognize the sequence R-G-D in their ligand
Integrin b5 ITGB5 Integrins are a large family of cell surface glycoproteins that mediate cell to cell and cell to matrix adhesion
Fibronectin FN1 Fibronectins bind cell surfaces and various compounds including collagen, ﬁbrin, heparin, DNA, and actin.
ﬁbronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell
shape
Collagen a-2
type I
COL1A2 Type I collagen is a member of group I collagen (ﬁbrillar forming collagen)
Signal pathway and transcriptor factors
FAK PTK2 Activation of focal adhesion kinases (FAK) may be an early step in intracellular signal transduction
pathways. This tyrosine-phosphorylation is triggered by integrin interactions with various extracellular matrix
(ecm) adhesive molecules and by neuropeptide growth factors. Potential role in oncogenic transformations
resulting in increased kinase activity
MAPK MAPK1 Phosphorylates microtubule-associated protein-2 (map2). Myelin basic protein (MBP), and elk-1; may
promote entry in the cell cycle
c-jun JUN Transcription factor that binds and recognize the enhancer DNA sequence: TGA(C/G)TCA
c-fos FOS Nuclear phosphoprotein, which forms a tight but non-covalently linked complex with the c-jun/ap-1
transcription factor. c-fos has a critical function in regulating the development of cells destined to form and
maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and
differentiation
PTK PTK9 —
PTK-receptor EPHA2 Receptor for members of the ephrin-a family. Binds to ephrin-a1, -a3, -a4 and -a5
STK-1 STK12 —
Growth factor and cytokines
FGF-2 FGF2 The heparin-binding growth factors are angiogenic agents in vivo and are potent mitogens for a variety of cell
types in vitro. There are differences in the tissue distribution and concentration of these 2 growth factors
FGF-5 FGF5 This oncogene is expressed in neonatal brain. FGF-5 can transform NIH 3T3 cells
FGF-7 FGF7 Growth factor active on keratinocytes. Possible major paracrine effector of normal epithelial cell proliferation
IGF-I IGF1 The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but
have a much higher growth-promoting activity
TGF-b TGFBI,
BIGH3
Binds to type I, II, and IV collagens. This adhesion protein may play an important role in cell–collagen
interactions. In cartilage, may be involved in endochondral bone formation
BMPs BMP4 Induces cartilage and bone formation
PDGF-A PDGFA Platelet-derived growth factor is a potent mitogen for cells of mesenchymal origin. Binding of this growth
factor to its afﬁnity receptor elicits a variety of cellular responses. It is released by platelets upon wounding
and plays an important role in stimulating adjacent cells to grow and thereby heal the wound
IL-1a IL1A Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell
maturation & proliferation, & ﬁbroblast growth factor activity. IL-1 proteins are involved in the
inﬂammatory response, being identiﬁed as endogenous pyrogens, and are reported to stimulate the release of
prostaglandin and collagenase from synovial cells
IL-6 IL6 It plays an essential role in the ﬁnal differentiation of b-cells into ig-secreting cells, it induces myeloma and
plasmacytoma growth, it induces nerve cells differentiation, in hepatocytes it induces acute phase reactants
PGE-2 PTGER1 Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G-Q proteins which
activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator
of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues
Cbfa1 RUNX2 Osteoblast-speciﬁc transcription factor
IHH IHH Intercellular signal essential for a variety of patterning events during development. Binds to the patched
(PTC) receptor, which functions in association with smoothened (SMO), to activate the transcription of target
genes. Implicated in endochondral ossiﬁcation: may regulate the balance between growth and ossiﬁcation of
the developing bones. Induces the expression of parathyroid hormone-related protein (PTHRP) (by
similarity)
BAPX1 BAPX1 Homeo box-containing gene,Drosophila bagpipe homolog, involved in mesodermal and skeletal development
ALP ALPPL2 Catalytic activity: an orthophosphoric monoester+h(2)o=an alcohol+orthophosphate (at a high pH
optimum)
SPARC SPARC Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds
calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There
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3.2.6. Apoptosis
NF-kB1 increased 1.51- and 1.31-fold for samples P48
and C48, respectively, then decreased at 120 h. NF-kB
p65 (Rel A) decreased with time. TFAR15 was up-
regulated 2.75- and 2.56-fold for samples P48 and
C48compared to A48. Bcl-xL was absent for samples
P48 and C48. It was down-regulated 0.14-fold for sample
C120 and decreased 0.90-fold for sample P120 compared
to A120. Bax isoform (alpha, beta, and delta) increased
with time and also increased for samples P120 and C120
compared to A120.
4. Discussion
cDNA microarray technology was used to obtain a
high-throughput of information on osteoblasts reaction
to different titanium surface treatments. In order to
have conﬁdence in the results, we have performed the
analysis of one sample (C24) twice with two Geneﬁlters.
Although not identical, a comparison of results showed
a good agreement of the gene expression values between
the two ﬁlters.
It has been shown that surface roughness inﬂuenced
the cell behaviour [19]. We have used XPS and AFM
techniques to examine the surface properties of the
treated Ti–6Al–4V surfaces [20]. A difference in rough-
ness (Ra) between the passivated and the aged samples
could only be observed at a small scale (1 mm2). The
area average Ra was about 0.99 nm (C), 1.29 nm (P)
and 0.56 nm (A). Therefore, at the cell level, the
roughness could be considered as similar between
samples and could not explain the differences in
osteoblasts behaviour. These differences are then
Table 3 (continued)
Gene Genecard Cellular function
are two calcium binding sites; a acidic domain that binds 5–8 Ca2+ with a low afﬁnity and a ef-hand loop that
binds a Ca2+ ion with a high afﬁnity
OPN SPP1 Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably
important to cell–matrix interaction
Biglycan BGN Found in the extracellular matrices of several connective tissues, specially in articular cartilages. The two
glycosaminoglycan chains attached to biglycan can be either chondroitin sulphate or dermatan sulphate
IBSP IBSP Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably
important to cell–matrix interaction. Promotes Arg–Gly Asp-dependent cell attachment
TRAIL TNFSF10 Induces apoptosis
NF-kB1 NFKB1 P105 is the precursor of the p50 subunit of the nuclear factor NF-kappa-b, which binds to the kappa-b
consensus sequence 50-ggrnnyycc-30, located in the enhancer region of genes involved in immune response and
acute phase reactions. The precursor protein itself does not bind to DNA
NF-kB p65 RELA p65 is a subunit of the nuclear factor kappa-b, a second messenger, which activates the transcription of a
number of genes in multiple tissues. The inhibitory effect of i-kappa-b upon NF-kappa-b in the cytoplasm is
exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could
contribute directly to DNA binding in the NF-kappa-b complex
OPG TNFSF11 Tumour necrosis factor superfamily, member 11 TNFRSF11A (RANK) and OPG (osteprogerin ligand),
localized in T cells bone marrow stromal cells, hypertrophic chondrocyte, stimulated by IL1B and
TNFRSF11B,expressed in bone, brain, heart, kidney, skeletal muscle, skin, cooperating with prostaglandin,
mediating osteoclastognesis and bone loss through systemic activation of T cells, regulating lymph node
organogenesis lymphocyte development and interactions between T cells and dendritic cells, activating the
antiapoptotic serine threonine kinase AKT/PKB through a signal complex involving TRAF6 and SRC
RANK TNFRSF11A
TRANCE TNFSF11
TFAK15 PDCD10 —
CSFs CSF1 Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling
the production, differentiation, and function of two related white cell populations of the blood, the
granulocytes and the monocytes-macrophages
Bcl-2 BCL2 (B-cell
CLL/
lymphoma 2)
Prolongs the survival of hematopoietic cells in the absence of required growth factors and also in the presence
of various stimuli inducing cellular death. Bcl2 blocks apoptosis because it interferes with the activation of
caspases by preventing the release of cytochrome c. might function in an antioxidant pathway to prevent
apoptosis at sites of free radical generation such as mitochondria
Bcl-xL BCL2L1 Dominant regulator of apoptotic cell death. The long form displays cell death repressor activity, whereas the
short isoform (-xS) promotes apoptosis
Bax BAX Accelerates programed cell death by binding to, and antagonizing the apoptosis repressor bcl-2 or its
adenovirus homolog e1b 19k protein. Induces the release of cytochrome c, activation of caspase-3, and
thereby apoptosis
TP53BP2 TP53BP2 Impedes cell cycle progression at G2/M
IGF-BP3 IGFBP3 IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the
growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface
receptors
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certainly due to the kinetics of ions release between
surface treatments.
4.1. Kinetics of genes modulation induced by the surface
treatment A
FAK and MAPK were down-regulated at 48 h.
Expression of these genes is related with integrin
expression in a time course of events according to the
Pathway 1 [21]
Integrins-FAK-MAPK-c-jun and c-fos
-Proliferation-Differentiation ðPathway 1Þ:
It has been demonstrated that osteoblasts cultured on
Ti–6Al–4V produce FAK and MAPK within 24 h [22].
According to our results, down-regulation of FAK and
MAPK at 48 h would not contradict the Pathway 1,
especially if integrins were not modulated which was the
case at 48 h. c-jun expression of osteoblasts cultured on
Ti–6Al–4V was also shown to be expressed before c-fos
[22]. In our experiment, we noted a down-regulation of
c-jun and an up-regulation of c-fos at 48 h, which is then
in accordance with the time course of events for c-jun
and c-fos expression. It is then reasonable to admit that
the osteoblast interaction with the surface treatment A
followed the Pathway 1.
The expression of PTK decreased over time. Indeed,
PTK has been showed to follow the Pathway 2 in
macrophages when metal particles were present [23]
Surface membrane receptors binding particles
-PTK and Serine=Threonine kinase
-NF-kB-Releasing TNF=IL-6 ðPathway 2Þ:
The osteoblasts also possess an inﬂammatory signaling
response similar to Pathway 2 [24]. Following the
decrease of PTK, we did not observe any modulation
of NF-kB or IL-6. It is possible that either the
concentration of metal ions released from the aged
sample is unable to stimulate the PTK pathway in
osteoblasts or the induced signal pathway is different
between particles and ions.
Several genes involved in the apoptosis process [25–
27] such as TRAIL, TRAIL-R3, RANK, TRANCE,
CSFs were not detected while NF-kB1, NF-kB p65,
TFAR15 had their expression decreased. In addition,
the up-regulation of Bcl-xL, which is an inhibitor of
apoptosis [28], increased with time. Conversely, the
expression of Bax, which can accelerate apoptosis [28],
decreased with time. These results could indicate that
the surface treatment A did not stimulate the activation
of apoptosis at 120 h. Therefore the survival of
osteoblasts could be enhanced on the aged surface
treatment. However, these results need to be conﬁrmed
by direct apoptosis measurement such as TUNEL assay.
Without the expression of NF-kB, or CSFs, osteo-
blasts are unable to secrete cytokines such as IL-1 or IL-
6 involved in the differentiation and apoptosis of
osteoclasts [25, 26, 29]. This conﬁrms the observation
of IL-1 or IL-6 expressions not being detected in our
experiment. Based on the genes studied in this experi-
ment, no stimulating effect of osteoblasts on osteoclasts
differentiation or activation through cytokine expres-
sion seems to be involved in the 120 h of this experiment.
4.2. Comparison of gene expression with respect to the
surface treatments C, P, A
Considering the genes involved in signal transduction,
FAK was up-regulated 4.25-fold for sample P48 and
6.63-fold for sample C48 while MAPK6 was up-
regulated 2.59-fold for sample C48 compared to A48.
For samples P48 and C48 c-jun increased and c-fos
decreased compared to A48. In addition, c-jun decreased
with time while c-fos increased in all samples. All these
modulations seem to indicate that samples P and C
delay the time course of gene expression in the Pathway
1 compared to the sample A. By extrapolating the time
course of gene expression in the Pathway 1, there should
be a decrease of cell proliferation for the samples C and
P compared to A. This is what we found in a previous
study [14], however using a different cell line rendering
direct comparison delicate. This delay in the gene
expression time course could be due to the decrease of
aluminium ions being released by the surface treatment
A [12] as it has been suggested that aluminium may alter
the timing/regulation of the proliferation/differentiation
transition point [30].
The expression of PTK9 was differentially modulated
according to the surface treatments with an up-regula-
tion for C48 and P48 compared to A48. In our previous
work [11], we showed that the surface treatment C
releases the highest amount of metal ions followed by
the surface treatment P then the surface treatment A.
Lending evidence that the up-regulation of PTK
followed exactly the same classiﬁcation. The up-regula-
tion of PTK was then directly related to the amount of
ions released. According to the Pathway 2, the surface
treatment A would then be more favourable by inducing
less inﬂammatory reaction than the surface treatment P
or C.
Recently, it has been demonstrated that Ti particles
induce osteoblast apoptosis [6]. Despite osteoblast
reaction to particles and ions may be different, we
investigated the possibility of apoptosis induced also by
ions. In the present study, no modulation of Bcl-xL was
detected for samples P48 and C48 compared to A48, while
it was down-regulated for P120 and C120 compared to
A120. On the other hand, the gene expression of Bax
isoform (alpha, beta, and delta) increased with time.
Osteoblast apoptosis could then be initiated from the
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high ratio of Bax to Bcl-xL. Based on these observa-
tions, osteoblasts may undergo more apoptosis on the
surface treatment P and the C at 120 h than on the
surface treatment A as a result of increased apoptotic
factors expression.
Based on the genes selected in this study, we propose a
general pathway of cell reaction according to the surface
treatments used:
(1) Metal ion release changes the time course of gene
expression in the FAK pathway (Pathway 1).
(2) Once the accumulation of metal ions released from
the Ti surface exceeds a threshold value, cell growth
is diminished and the apoptosis process may be
activated.
(3) Metal ion release upregulates PTK (Pathway 2).
(4) The expression of Bcl-2 family and Bax may suggest
that metal ions induce the apoptosis process.
5. Conclusions
The signiﬁcant gene expression of collagen, FAK,
MAPK, FGF-5, IGF-I and Bcl-xL demonstrated that
primary human osteoblastic cells were active on the aged
Ti–6Al–4V implants.
Although several apoptotic genes were expressed
during the test, none of them continuously increased
with time, except Bax, which suggests that Bax plays a
signiﬁcant role in the effects of metal ions on apoptosis.
Considering the experimental design, it has been
found that most of the signiﬁcant modulation took place
before 48 h. Therefore, to determine the critical point of
gene expression in the different pathways future
genomic biocompatibility testing should be performed
before 48 h following cell seeding.
Finally, the developed surface treatment A seems to
increase Ti–6Al–4V biocompatibility. This is highlighted
by the lower impact of this treatment on the different
pathways studied, by the lower inﬂammatory reaction,
as well as by the lower induced osteoblast apoptosis
compared to the surface treatment C and P.
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